VISICORT presentation in Berlin aims to recruit potential patients to the clinical trial

VISICORT PI Uwe Pleyer at Charité Universitätsmedizin Berlin organized a seminar entitled “Autologe Stammzelltherapie zur Prophylaxe der Immunreaktion bei Risikokeratoplastik”. The Anterior Segment Symposium on April 27th, 2019 in Berlin included a presentation on the VISICORT project with the aim to recruit potential patients for the Phase 1 trial.


Pictured above Prof. Dr Rieck and Prof. Dr Uwe Pleyer

VISICORT trial news announced in ARM March newsletter

The Alliance for Regenerative Medicine’s March 14, 2019 newsletter included a recent update on the VISICORT clinical trial regulatory approval. You can read the piece in the newsletter’s Clinical Updates section.

VISICORT Clinical Trial is now fully approved and ready for launch!

The VISICORT project has reached an exciting milestone having recently received regulatory and ethical approval to proceed with the first clinical trial of a cell therapy in high-risk corneal transplantation.

To prepare for the launch of the trial, Prof. Matthew Griffin, Prof. Thomas Ritter, Dr. Siobhan Gaughan and Ms Aoife Duffy of NUI Galway, Ireland and Mr. Peadar Mac Gabhann of Biostór Ireland Ltd. visited the CHARITÉ RESEARCH ORGANISATION (CRO), in Berlin on Thursday 28th February 2019 (see picture)  The meeting was hosted by the CRO clinical trial team of Dr. Andreas Hüser, Dr. Rita Hertrampf, Ms Juliane Schnorr, Dr. Maximilian Posch and Ms. Jeanette Lehmann and by Prof. Uwe Pleyer of the Department of Ophthalmology, Charité University Medical Centre, who will be the principal investigator for the trial.

The VISICORT trial will be a Phase 1B clinical trial to test the safety and feasibility of intravenous allogeneic mesenchymal stromal cells (allo-MSC) as an immunotherapy for  patients receiving a second or greater full-thickness corneal transplant who are at high risk of rejection. If the trial demonstrates that allo-MSC therapy is well tolerated in high-risk corneal transplant recipients, it will open the door to a Phase 2 trial to more clearly test its potential to reduce the occurrence of rejection and promote the long-term survival of repeat corneal transplant.

Fittingly, the trial will be carried out at Charité University where some of the most important early  advances in the treatment of eye disease were made by the pioneering ophthalmologist, Prof. Albrecht von Graefe, in the 19th century (see photo below).   

During the meeting, the VISICORT partners discussed and agreed on many of the organisational details of the trial and developed a time-line for allo-MSC manufacture and patient enrolment over the next year. The VISICORT clinical trial team are looking forward to meeting up again for further discussions with the entire consortium at a Plenary Meeting which will be held in Galway on Thursday 14th and Friday 15th March 2019.